Coya Therapeutics (COYA) shares fell nearly 23% in recent Tuesday trading after the company reported results from its phase 2 trial of LD IL-2 in patients with mild to moderate Alzheimer's Disease.
The placebo-controlled study evaluated two dosing regimens of subcutaneous low-dose interleukin-2, or IL-2. The trial met its primary and secondary goals for safety and enhancing regulatory T cell, or Treg, populations, respectively, the company said.
The higher total dose group, however, "did not exhibit benefits in exploratory endpoints, underscoring the importance of appropriate IL-2 dosing for maintaining Treg functionality and its associated effects on cerebrospinal fluid biomarkers and cognitive outcomes," the company said.
Exploratory endpoints of the study examined changes in cerebrospinal fluid, Alzheimer's Disease-related biomarkers, and cognitive status, the company added.
Price: 7.87, Change: -2.33, Percent Change: -22.82
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.